PRINCETON, N.J. / Nov 24, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that, following the conclusion of the American Society of Hematology (ASH) Annual Meeting and Exposition, the company will hold a virtual investor event on Thursday, December 11, 2025, to highlight key Hematology programs.
The company will host a webcast beginning at 9:00 a.m. ET, which is accessible here. Company representatives will provide investors and analysts an overview of the company’s Hematology development strategy and review recent data.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the event concludes. Materials related to the webcast will be available at http://investor.bms.com at the start of the presentation.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$48.16 |
| Daily Change: | 1.91 4.13 |
| Daily Volume: | 13,195,061 |
| Market Cap: | US$98.240B |
November 03, 2025 October 13, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
